Andere talen Ocuphire Pharma, Inc.

Aandelen

OCUP

US67577R1023

Geschatte realtime Cboe BZX Andere beurzen 20:35:10 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,865 ^USD	+13,72%		+20,52%	-38,54%

11/04	Ocuphire Pharma neemt 1e patiënt op in Fase 3 studie voor behandeling van gezichtsscherpte	MT
11/04	Ocuphire Pharma, Inc. kondigt wereldwijde licentieovereenkomst aan met Viatris Inc.	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting	22/04
Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment	11/04
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery	11/04
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	11/04
Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study	11/04
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris	01/04
Ocuphire Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	08/03
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update	08/03
Ocuphire Pharma to Present in the BIO CEO and Investor Conference	26/02
Ocuphire Pharma to Present in the BIO CEO & Investor Conference	23/02
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	15/02
Ocuphire Pharma Appoints CFO, Science Chief	14/02
Ocuphire Pharma Strengthens Leadership Team with Key Appointments	14/02
Ocuphire Pharma, Inc. Announces Appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer	14/02
Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer	14/02
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference	05/02
Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy	05/02
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	24/01
Ocuphire Pharma, Inc. Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity Under Dim Light Conditions	04/01
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions	04/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ocuphire Pharma, Inc.

Aandelen

OCUP

US67577R1023

Andere talen

Filters